Peroxovanadium compounds: Biological actions and mechanism of insulin-mimesis
When used alone, both vanadate and hydrogen peroxide (H2O2) are weakly insulin-mimetic, while in combination they are strongly synergistic due to the formation of aqueous peroxovanadium species pV(aq). Administration of these pV(aq) species leads to activation of the insulin receptor tyrosine kinase (IRK), autophosphorylation at tyrosine residues and inhibition of phosphotyrosine phosphatases (PTPs). We therefore undertook to synthesize a series of peroxovanadium (pV) compounds containing one or two peroxo anions, an oxo anion and an ancillary ligand in the inner co-ordination sphere of vanadium, whose properties and insulin-mimetic potencies could be assessed. These pV compounds were shown to be the most potent inhibitors of PTPs yet described. Their PTP inhibitory potency correlated with their capacity to stimulate IRK activity. Some pV compounds showed much greater potency as inhibitors of insulin receptor (IR) dephosphorylation than epidermal growth factor receptor (EGFR) dephosphorylation, implying relative specificity as PTP inhibitors. Replacement of vanadium with either molybdenum or tungsten resulted in equally potent inhibition of IR dephosphorylation. However IRK activation was reduced by greater than 80% suggesting that these compounds did not access intracellular PTPs. The insulin-like activity of these pV compounds were demonstrable in vivo. Intra venous (i.v.) administration of bpV(pic) and bpV(phen) resulted in the lowering of plasma glucose concentrations in normal rats in a dose dependent manner. The greater potency of bpV(pic) compared to bpV(phen) was explicable, in part, by the capacity of the former but not the latter to act on skeletal muscle as well as liver. Finally administration of bpV(phen) and insulin led to a synergism, where tyrosine phosphorylation of the IR β-subunit increased by 20-fold and led to the appearance of four insulin-dependent in vivo substrates. The insulin-mimetic properties of the pV compounds raises the possibility for their use as insulin replacements in the management of diabetes mellitus.
Key wordsinsulin receptor tyrosine kinase peroxovanadium insulin-mimetic phosphotyrosine phosphatase
Unable to display preview. Download preview PDF.
- 18.Heflfetz D, Zick Y: H2O2 potentiates phosphorylation of novel putative substrates for the insulin receptor kinase in intact Fao cells. J Biol Chem 264: 10126–10132, 1989Google Scholar
- 23.Hadari YR, Geiger B, Nadiv O, Sabanay I, Roberts CTJ, LeRoith D, Zick Y: Hepatic tyrosine-phosphorylated proteins identified and localized following in vivo inhibition of protein tyrosine phosphatases: effects of H2O2 and vanadate administration into rat livers. Mol Cell Endocrinol 97: 9–17, 1993PubMedCrossRefGoogle Scholar
- 24.Posner Bl, Faure R, Burgess JW, Bevan AP, Lachance D, Zhang-Sun G, Fantus IG, Ng JB, Hall DA, Lum BS, Shaver A: Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. J Biol Chem 269: 4596–4604, 1994Google Scholar
- 35.Shaver A, Ng JB, Hall DA, Lum BS, Posner Bl: Insulin mimetic peroxovanadium complexes: preparation and structure of potassium oxodiperoxo (pyridine-2-carboxylato) vanadate(V), K2[VO(O2)2(C5H4NCOO)]·2H2O, and potassium oxodiperoxo(3-hydro-ypyridine-2-carboxylato)vanadate(V), K2[VO(O2)2(OHC5H3NCOO)].3H2O, and their reactions with cysteine. Inorg Chem 32: 3109–3113, 1993CrossRefGoogle Scholar
- 48.Estrada DE, Elliott E, Zinman B, Poon I, Liu Z, Klip A, Daneman D: Regulation of glucose transport and expression of GLUT3 transporters in human circulating mononuclear cells: studies in cells from insulin-dependent diabetic and nondiabetic individuals. Metabolism 43: 591–598, 1994PubMedCrossRefGoogle Scholar